Terug naar bedrijfspagina

Nieuws over Mithra Women's Health

11/06/2024 Mithra - files for bankruptcy and continues negotiations with Gedeon Richter for the sale of Neuralis and Estetra (11.06.2024)

11/06/2024 Mithra - sells Estetra SRL, Neuralis SA and specific assets to Gedeon Richter (11.06.2024)

04/06/2024 Mithra - applies for extension of court protection measures to advance monetization process (04.06.2024)

29/05/2024 Mithra - receives additional EUR 2.5 million to advance monetization (29.05.2024)

28/05/2024 Mithra - postpones its annual general meeting (28.05.2024)

10/05/2024 Mithra - announces grant of two additional U.S. patents for NEXTSTELLIS (10.05.2024)

03/05/2024 Mithra - enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process (03.05.2024)

29/04/2024 Mithra - updates on offers received in the context of its monetization process and on its Annual Report 2023 (29.04.2024)

22/04/2024 Mithra secures court protection measures to advance monetization process (22.04.2024)

16/04/2024 Mithra - Early data from Mithra’s ESTELLE pediatric study to be presented at two upcoming congresses (16.04.2024)

08/04/2024 Mithra - reaches milestone in estetrol skin study (08.04.2024)

28/03/2024 Mithra - updates on its ongoing monetization process (28.03.2024)

08/03/2024 Mithra - reports full year 2023 financial results (08.03.2024)

05/03/2024 Mithra - announces changes to its executive management - initiates monetization process, receives bridge loan from existing lenders (05.03.2024)

28/02/2024 MITHRA - DONESTA safety study for menopause completes treatment phase and advances to data management & reporting phase (28.02.2024)

15/02/2024 Mithra - sells shares in Mayne Pharma (15.02.2024)

06/02/2024 Mithra - updates on cash position (06.02.2024)

21/12/2023 Mithra - Completes Pediatric Study of ESTELLE® in Adolescent Patients (21.12.2023)

21/12/2023 Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA in Israel (21.12.2023)

18/12/2023 Mithra - Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial (18.12.2023)

04/12/2023 Mithra - and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China (04.12.2023)

30/11/2023 Mithra - receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States (30.11.2023)

28/11/2023 Mithra - to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam (28.11.2023)

23/11/2023 Mithra - announces results of the 23 November 2023 Extraordinary General Meeting (23.11.2023)

07/11/2023 Mithra’s NEXTSTELLIS granted additional patent in the United States (07.11.2023)